Renfu Pharmaceutical (600079.SH): The injection of metaproterenol sulfate has obtained the drug registration certificate.

Intelligence Finance APP News: Renfu Medicine (600079.SH) announced that its controlling subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (referred to as "Yichang Renfu", of which the company holds 80% of the equity), recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of Metaraminol Bitartrate Injection. The approval of Metaraminol Bitartrate Injection marks the company's eligibility to sell the drug in the domestic market, further enriching the company's product line, and its listing for sale will bring positive impact to the company.